Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
CD279 [PD-1] (human):Fc (human) (rec.)
Product Details | |
---|---|
Synonyms | PD-1; Programmed Cell Death Protein 1 |
Product Type | Protein |
Properties | |
Source/Host | CHO cells |
Sequence |
The extracellular domain of human CD279 [PD-1] (aa 25-167) is fused to the N-terminus of the Fc region of human IgG1. |
Crossreactivity | Human |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized rhPDL1-His at 20µg/ml (50µl/well) binds to rhPD1-Fc (CHI-HF-210PD1) with an EC50 of ~1.2µg/ml. |
MW | ~50-70kDa |
Purity | ≥98% (SDS-PAGE) |
Endotoxin Content | <1EU/mg protein (LAL test; Lonza). |
Reconstitution | Reconstitute with 100 µl sterile water. Add 1X PBS to the desired protein concentration. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Protein Negative Control | |
Other Product Data |
NCBI reference NP_005009.2: CD279 (human) |
Declaration | Manufactured by Chimerigen. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD279 (Programmed Cell Death Protein 1; PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-γ. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.